SCHEMBL25371019

SCHEMBL25371019

CCOC(=O)CCC(=O)c1nc(Cc2ccccc2)ccc1O

nearest known ligand 0.44

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
LTA4H P09960 8/20 0.44
KMT2A Q03164 2/20 0.41
MEN1 O00255 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
MAPT P10636 2/20 0.41
L3MBTL1 Q9Y468 2/20 0.41
PRNP P04156 1/20 0.41
RXFP1 Q9HBX9 1/20 0.41
TOP2A P11388 1/20 0.40
PPARG P37231 1/20 0.40
PPARD Q03181 1/20 0.40
PPARA Q07869 1/20 0.40
ALOX5 P09917 1/20 0.39
TRPM8 Q7Z2W7 1/20 0.39
CYP1A2 P05177 1/20 0.39
CYP3A4 P08684 1/20 0.39
CYP2C9 P11712 1/20 0.39
CYP2C19 P33261 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25372419 0.93 LTA4H (0.41) LTA4HKMT2ASMN1; SMN2MAPTL3MBTL1
SCHEMBL29395974 0.93 LTA4H (0.41) LTA4HKMT2ASMN1; SMN2MAPTL3MBTL1
SCHEMBL25372395 0.93 TRPM8 (0.41) LTA4HSMN1; SMN2L3MBTL1TRPM8
SCHEMBL25374073 0.90 CYP4F2 (0.39) LTA4HKMT2AMEN1SMN1; SMN2MAPT
SCHEMBL29395604 0.90 ACMSD (0.40) LTA4HSMN1; SMN2L3MBTL1PPARGPPARD
SCHEMBL25373512 0.90 ACMSD (0.40) LTA4HSMN1; SMN2L3MBTL1PPARGPPARD
SCHEMBL25372814 0.89 ALOX5 (0.44) SMN1; SMN2MAPTL3MBTL1TOP2APPARG
SCHEMBL25372455 0.89 KMT2A (0.40) KMT2AMEN1SMN1; SMN2L3MBTL1PPARG
SCHEMBL25372542 0.88 TDP1 (0.39) LTA4HKMT2AMEN1MAPTL3MBTL1
SCHEMBL25372307 0.88 MAPT (0.42) KMT2AMEN1SMN1; SMN2MAPTL3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240002344-A1 COMPOUNDS, COMPOSITIONS AND METHODS FOR HISTONE LYSINE DEMETHYLASE INHIBITION FIBROGEN, INC. 2024-01-04 US disclosed
EP-4204400-A1 COMPOUNDS, COMPOSITIONS AND METHODS FOR HISTONE LYSINE DEMETHYLASE INHIBITION Fibrogen, Inc. (US) 2023-07-05 EP disclosed
CN-116348450-A Compounds, compositions and methods for histone lysine demethylase inhibition 菲布罗根有限公司 2023-06-27 CN disclosed
WO-2022047230-A1 COMPOUNDS, COMPOSITIONS AND METHODS FOR HISTONE LYSINE DEMETHYLASE INHIBITION FIBROGEN, INC. (US) 2022-03-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240002344-A1 COMPOUNDS, COMPOSITIONS AND METHODS FOR HISTONE LYSINE DEMETHYLASE INHIBITION KDM5C, KDM5B, KDM5A LTA4H 2551/4885KMT2A 36/4885MEN1 3933/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.